fbpx
01 / 05
Lab-Grown Oesophagus Restores Pigs’ Ability to Swallow

Nature | Health & Medical Care

Lab-Grown Oesophagus Restores Pigs’ Ability to Swallow

“Scientists have used stem cells to make bioengineered oesophagi that they successfully implanted into pigs, restoring the animals’ ability to swallow and eat. Similar lab-grown structures could be used to treat people with cancer and other conditions affecting the muscular tube that connects the throat to the stomach, researchers say.

Paolo De Coppi, a paediatric surgeon and researcher at University College London, says his team has been investigating minimally invasive ways to treat children born with a large hole in their oesophagus, a condition called long-gap oesophageal atresia. The current treatment is to move the child’s stomach up to their neck and join it directly to the back of their throat, or to transplant part of their colon to bridge the gap.

De Coppi and his colleagues have previously grown mouse cells on a rat oesophagus and implanted them into mice. They have also transplanted the pig-based scaffold into rabbits. The team’s latest work, published in Nature Biotechnology today, involved transplanting sections of oesophagus that had been grown in the lab into pigs, which are better than rodents as a model for humans, because of their size and physiology.”

From Nature.

Medical Xpress | Vaccination

mRNA-1010 Superior to Standard-Dose Vaccine for Preventing Flu

“For adults aged 50 years or older, an investigational messenger RNA (mRNA)-based vaccine (mRNA-1010) is superior to standard-dose licensed vaccines for preventing influenza-like illness, according to a study published in the New England Journal of Medicine

Overall, 20,350 participants received mRNA-1010 and 20,353 received the standard-dose comparator. The researchers found that 2.0% and 2.8% of the recipients of mRNA-1010 and the standard-dose comparator, respectively, had RT-PCR-confirmed, protocol-defined influenza-like illness, corresponding to a relative vaccine efficacy of 26.6% and meeting the criteria for noninferiority, superiority, and higher-level superiority. Solicited adverse reactions occurred more often with mRNA-1010 than the standard-dose comparator; they were mainly mild-to-moderate and transient. Overall, 2.2% and 1.9% of recipients of mRNA-1010 and the standard-dose comparator, respectively, had serious adverse events.”

From Medical Xpress.

Science | Health Systems

AI Is Starting to Beat Doctors at Making Correct Diagnoses

“If you walk into an emergency room (ER) in 10 years, you’ll encounter a new type of caregiver: an artificial intelligence (AI) system designed to get you a diagnosis faster and help your care team make more informed decisions. While you sit in the waiting room, you’ll be hooked up to a blood pressure cuff that’s constantly and autonomously monitored. All the while, an AI agent will be listening in while you and your doctor talk about your symptoms, ready to flag any mistakes your physician makes or suggest next steps.

This vision of AI-assisted emergency health care may soon be reality. In a new study, researchers show that a type of AI known as a large language model (LLM) often outperformed physicians at diagnosing complex and potentially life-threatening conditions, including decreased blood flow to the heart, even in the fast-moving stages of real ER care when information is limited, they report today in Science. In early ER cases, the model identified the correct or a very close diagnosis in about 67% of cases, compared with roughly 50% to 55% for physicians. And the technology is only getting better.”

From Science.

The Guardian | Health Systems

First Malaria Drug for Babies Is Approved in Major Milestone

“The first malaria treatment for babies has been approved by the World Health Organization, opening the door to widespread use around the globe.

In parts of Africa, up to 18% of children under six months will be infected with malaria, but there has historically been no safe treatment for the smallest of them. There were 610,000 deaths from malaria in 2024, about three quarters of which were under-fives in Africa…

Medical leaders hope that Coartem Baby, which can be used to treat infants as small as 2kg (4.4lb), will fill the treatment gap. The drug comes as sweet cherry-flavoured tablets that can be dissolved into liquids, including breast milk…

Coartem Baby now has WHO prequalification, which indicates it meets international standards of quality, safety and efficacy, and will enable public-sector procurement for many countries with high rates of malaria, particularly in sub-Saharan Africa.”

From The Guardian.

Gavi | Vaccination

Burkina Faso Celebrates Malaria Vaccine Impact

“Authorities report an unprecedented decline in malaria rates at the national level. At a press briefing in February 2026, Health Minister Robert Kargougou said the total number of recorded malaria cases fell from 10,805,020 in 2024, to 7,329,278 in 2025, a decrease of 32%. Over the same period, deaths fell from 3,523 to 1,979, a drop of 44%. Among children under five, cases declined by 39%, while mortality fell by more than 40%.”

From Gavi.